These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 29110391)
1. Th2 axis-related cytokines in patients with neuromyelitis optica spectrum disorders. Zhang Y; Yao XY; Gao MC; Ding J; Hong RH; Huang H; Zhuang L; Wang YG; Hao Y; Guan YT CNS Neurosci Ther; 2018 Jan; 24(1):64-69. PubMed ID: 29110391 [TBL] [Abstract][Full Text] [Related]
2. Low levels of vitamin D and the relationship between vitamin D and Th2 axis-related cytokines in neuromyelitis optica spectrum disorders. Gao M; Yao X; Ding J; Hong R; Wu Y; Huang H; Zhuang L; Li Z; Wang Y; Zhang Y; Guan Y J Clin Neurosci; 2019 Mar; 61():22-27. PubMed ID: 30692037 [TBL] [Abstract][Full Text] [Related]
3. Cytokine and Chemokine Profiles in Patients with Neuromyelitis Optica Spectrum Disorder. Wang Y; Zhou Y; Sun X; Lu T; Wei L; Fang L; Chen C; Huang Q; Hu X; Lu Z; Peng L; Qiu W Neuroimmunomodulation; 2016; 23(5-6):352-358. PubMed ID: 28445879 [TBL] [Abstract][Full Text] [Related]
4. Decreased serum IL-27 and IL-35 levels are associated with disease severity in neuromyelitis optica spectrum disorders. Zhang DQ; Jia K; Wang R; Li T; Zhao N; Yang LN; Yang L J Neuroimmunol; 2016 Apr; 293():100-104. PubMed ID: 27049569 [TBL] [Abstract][Full Text] [Related]
5. Lower serum interleukin-22 and interleukin-35 levels are associated with disease status in neuromyelitis optica spectrum disorders. Yang H; Han L; Zhou YJ; Ding J; Cai Y; Hong RH; Hao Y; Zhu DS; Shen XF; Guan YT CNS Neurosci Ther; 2020 Feb; 26(2):251-259. PubMed ID: 31342670 [TBL] [Abstract][Full Text] [Related]
6. Correlation between serum levels of endothelin-1 and disease severity in patients with neuromyelitis optica spectrum disorders. Yi M; Liu MQ; Chou LS; Jiang SM; Zhang LJ; Huang CN; Wang N; Zhang QX; Yang L Immunobiology; 2020 May; 225(3):151959. PubMed ID: 32517881 [TBL] [Abstract][Full Text] [Related]
7. EBI2-expressing B cells in neuromyelitis optica spectrum disorder with AQP4-IgG: Association with acute attacks and serum cytokines. Baek SH; Kim B; Shin JY; Choi SJ; Ahn SH; Choi YS; Kim SM; Sung JJ J Neuroimmunol; 2021 Sep; 358():577637. PubMed ID: 34229205 [TBL] [Abstract][Full Text] [Related]
8. Cytokines and Tissue Damage Biomarkers in First-Onset Neuromyelitis Optica Spectrum Disorders: Significance of Interleukin-6. Wei Y; Chang H; Li X; Wang H; Du L; Zhou H; Xu W; Ma Y; Yin L; Zhang X Neuroimmunomodulation; 2018; 25(4):215-224. PubMed ID: 30544111 [TBL] [Abstract][Full Text] [Related]
9. Increased serum IL-36β and IL-36γ levels in patients with neuromyelitis optica spectrum disorders: association with disease activity. Yang CS; Zhang QX; Deng Y; Zhou BJ; Zhang LJ; Li LM; Qi Y; Wang J; Yang L; Shi FD BMC Neurol; 2019 Aug; 19(1):185. PubMed ID: 31382910 [TBL] [Abstract][Full Text] [Related]
10. Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder. Kong BS; Kim Y; Kim GY; Hyun JW; Kim SH; Jeong A; Kim HJ J Neuroinflammation; 2017 Sep; 14(1):191. PubMed ID: 28946890 [TBL] [Abstract][Full Text] [Related]
12. Elevated serum interleukin-39 levels in patients with neuromyelitis optica spectrum disorders correlated with disease severity. Yang MG; Tian S; Zhang Q; Han J; Liu C; Zhou Y; Zhu J; Jin T Mult Scler Relat Disord; 2020 Nov; 46():102430. PubMed ID: 32853892 [TBL] [Abstract][Full Text] [Related]
13. Anti-aquaporin-4 titer is not predictive of disease course in neuromyelitis optica spectrum disorder: A multicenter cohort study. Kessler RA; Mealy MA; Jimenez-Arango JA; Quan C; Paul F; López R; Hopkins S; Levy M Mult Scler Relat Disord; 2017 Oct; 17():198-201. PubMed ID: 29055457 [TBL] [Abstract][Full Text] [Related]
14. The levels of circulating cytokines and risk of neuromyelitis optica spectrum disorder: a Mendelian randomization study. Ma X; Wang Y; Chen X; Guo J Front Immunol; 2024; 15():1418309. PubMed ID: 39011048 [TBL] [Abstract][Full Text] [Related]
15. Association of Circulating Follicular Helper T Cells and Serum CXCL13 With Neuromyelitis Optica Spectrum Disorders. Yang X; Peng J; Huang X; Liu P; Li J; Pan J; Wei Z; Liu J; Chen M; Liu H Front Immunol; 2021; 12():677190. PubMed ID: 34335576 [TBL] [Abstract][Full Text] [Related]
16. Resolution of inflammation in neuromyelitis optica spectrum disorders. Wang X; Jiao W; Lin M; Lu C; Liu C; Wang Y; Ma D; Wang X; Yin P; Feng J; Zhu J; Zhu M Mult Scler Relat Disord; 2019 Jan; 27():34-41. PubMed ID: 30300851 [TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea. Seok JM; Cho HJ; Ahn SW; Cho EB; Park MS; Joo IS; Shin HY; Kim SY; Kim BJ; Kim JK; Cho JY; Huh SY; Kwon O; Lee KH; Kim BJ; Min JH Mult Scler; 2017 Nov; 23(13):1748-1756. PubMed ID: 28058965 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-36 alpha levels are elevated in the serum and cerebrospinal fluid of patients with neuromyelitis optica spectrum disorder and correlate with disease activity. Song Y; Zhu M; Liu C; Zheng C; Zhou Y; Zhu J; Jin T Immunobiology; 2019 May; 224(3):397-401. PubMed ID: 30852049 [TBL] [Abstract][Full Text] [Related]
19. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Kitley J; Leite MI; Nakashima I; Waters P; McNeillis B; Brown R; Takai Y; Takahashi T; Misu T; Elsone L; Woodhall M; George J; Boggild M; Vincent A; Jacob A; Fujihara K; Palace J Brain; 2012 Jun; 135(Pt 6):1834-49. PubMed ID: 22577216 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic Response and Possible Biomarkers in Acute Attacks of Neuromyelitis Optica Spectrum Disorders: A Prospective Observational Study. Wang J; Cui C; Lu Y; Chang Y; Wang Y; Li R; Shan Y; Sun X; Long Y; Wang H; Wang Z; Lee M; He S; Lu Z; Qiu W; Tan S Front Immunol; 2021; 12():720907. PubMed ID: 34421925 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]